[The role of Foxo1 and ubiquitin-proteasome system markers in muscle atrophy caused by chronic kidney disease]

other public-domain-us
View on PubMed

Abstract

OBJECTIVE: To identity whether there is muscle atrophy phenomenon in end-stage kidney disease patients and to detect the level of transcription factor Foxo1 and the activity of ubiquitin-proteasome system. METHODS: Twenty-two patients in chronic kidney disease (CKD) stage 5 were selected and their mean muscle cross sectional area was measured. mRNA and protein levels of Foxo1, Atrogin-1, MuRF1 in rectus abdominis biopsies obtained from consecutive patients were detected. Control biopsies were obtained from 8 healthy subjects during elective surgery for abdominal wall hernias and 6 subjects during elective surgery for adenomyosis. RESULTS: Compared with the control group, cross sectional area of muscle fibers decreased and the transcription and protein levels of Foxo1, Atrogin-1, MuRF1 were upregulated in CKD group (P < 0.05). Protein level of p-Foxo1 decreased in CKD group (P < 0.05). CONCLUSION: There exist muscle atrophy phenomenon in CKD patients, which may associate with the upregulation of Foxo1 and activation of ubiquitin-proteasome system.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Forkhead Transcription Factors Kidney Failure, Chronic Kidney Failure, Chronic Muscular Atrophy Proteasome Endopeptidase Complex Case-Control Studies Female Forkhead Box Protein O1 Forkhead Transcription Factors Humans Kidney Failure, Chronic Male Middle Aged Muscle Proteins Muscle Proteins Muscular Atrophy Proteasome Endopeptidase Complex Rectus Abdominis Rectus Abdominis SKP Cullin F-Box Protein Ligases

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-21T06:12:49.409960+00:00
pubmed
last seen: 2026-05-13T22:18:35.150238+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine